Cantor Fitzgerald reissued their neutral rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research report report published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $245.00 price target on the electric vehicle producer’s stock. Other equities analysts also recently issued reports about the company. William Blair started coverage on Tesla […]

Cantor Fitzgerald reissued their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $90.00 price target on the stock. A number of other equities research analysts also recently weighed in on CRNX. Piper Sandler reaffirmed an overweight […]

Cantor Fitzgerald restated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research note released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $116.00 price objective on the biopharmaceutical company’s stock. RARE has been the topic of several other reports. Canaccord Genuity Group reaffirmed a buy rating and […]